Am J Blood Res 2012;2(2):105-112
Review Article
Detection of minimal residual disease in hematopoietic progenitor cell
harvests: lack of predictive value of peripheral blood and bone marrow
analysis in mantle cell and indolent lymphoma
Michele Magni, Massimo Di Nicola, Carmelo Carlo-Stella, Paola Matteucci, Liliana Devizzi, Anna Guidetti, Fernando
Ravagnani, Alessandro M Gianni
Division of Medical Oncology, Bone Marrow Transplantation Unit; Department of Pathology, Laboratory and Transfusion
Medicine, Immunohematology and Transfusion Medicine Service, Fondazione IRCCS, Istituto Nazionale per lo Studio e la
Cura dei Tumori, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas,
IRCCS, Rozzano (MI), Italy; Chair of Oncology, University of Milan, Milan, Italy
Received February 20, 2012; accepted March 19, 2012; Epub April 15, 2012; Published June 15, 2012
Abstract: Elimination of neoplastic cells from peripheral blood progenitor cells (PBPCs) is an important issue in
transplantation-based high-dose chemotherapy in non Hodgkin’s lymphoma (NHL). The capacity to reliably assess the
presence of residual lymphoma cells in PBPCs is mandatory in designing this type of protocols. Polymerase chain reaction
(PCR) amplification of molecular rearrangements is widely used to detect minimal residual disease (MRD) in NHL patients.
Although concordant data can be obtained in most of the cases from peripheral blood (PB) and bone marrow (BM) at
diagnosis, the relationship between these two compartments and the role of their analysis in predicting the molecular status
of PBPCs is still an open issue. Here we report data about MRD analysis in BM, PB and PBPCs in a series of mantle cell and
indolent NHL patients who underwent high-dose chemotherapy: discordant results were obtained comparing PB, BM and
PBPC molecular data. In addition, differences were noted among these results if molecular analysis was performed using
well-known rearrangements (i.e., bcl-1/IgH and bcl-2/IgH) or patient specific oligonucleotides. We conclude that neither BM
nor PB are reliable in predicting the molecular status of PBPCs and that caution must be adopted in interpreting molecular
data obtained using patient specific oligonucleotides. (AJBR1202001)
Keywords: Minimal residual disease, peripheral blood, bone marrow, peripheral blood progenitor cells
Address all correspondence to:
Dr. Michele Magni
Division of Medical Oncology
Istituto Nazionale Tumori, via Venezian 1
20133 Milan, Italy.
Tel: +39-02-23902175; Fax: +39-02-23902678
E-mail: michele.magni@istitutotumori.mi.it
Review Article
Detection of minimal residual disease in hematopoietic progenitor cell
harvests: lack of predictive value of peripheral blood and bone marrow
analysis in mantle cell and indolent lymphoma
Michele Magni, Massimo Di Nicola, Carmelo Carlo-Stella, Paola Matteucci, Liliana Devizzi, Anna Guidetti, Fernando
Ravagnani, Alessandro M Gianni
Division of Medical Oncology, Bone Marrow Transplantation Unit; Department of Pathology, Laboratory and Transfusion
Medicine, Immunohematology and Transfusion Medicine Service, Fondazione IRCCS, Istituto Nazionale per lo Studio e la
Cura dei Tumori, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas,
IRCCS, Rozzano (MI), Italy; Chair of Oncology, University of Milan, Milan, Italy
Received February 20, 2012; accepted March 19, 2012; Epub April 15, 2012; Published June 15, 2012
Abstract: Elimination of neoplastic cells from peripheral blood progenitor cells (PBPCs) is an important issue in
transplantation-based high-dose chemotherapy in non Hodgkin’s lymphoma (NHL). The capacity to reliably assess the
presence of residual lymphoma cells in PBPCs is mandatory in designing this type of protocols. Polymerase chain reaction
(PCR) amplification of molecular rearrangements is widely used to detect minimal residual disease (MRD) in NHL patients.
Although concordant data can be obtained in most of the cases from peripheral blood (PB) and bone marrow (BM) at
diagnosis, the relationship between these two compartments and the role of their analysis in predicting the molecular status
of PBPCs is still an open issue. Here we report data about MRD analysis in BM, PB and PBPCs in a series of mantle cell and
indolent NHL patients who underwent high-dose chemotherapy: discordant results were obtained comparing PB, BM and
PBPC molecular data. In addition, differences were noted among these results if molecular analysis was performed using
well-known rearrangements (i.e., bcl-1/IgH and bcl-2/IgH) or patient specific oligonucleotides. We conclude that neither BM
nor PB are reliable in predicting the molecular status of PBPCs and that caution must be adopted in interpreting molecular
data obtained using patient specific oligonucleotides. (AJBR1202001)
Keywords: Minimal residual disease, peripheral blood, bone marrow, peripheral blood progenitor cells
Address all correspondence to:
Dr. Michele Magni
Division of Medical Oncology
Istituto Nazionale Tumori, via Venezian 1
20133 Milan, Italy.
Tel: +39-02-23902175; Fax: +39-02-23902678
E-mail: michele.magni@istitutotumori.mi.it
| AJBR Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 |  |  |  |  |  |  |